Coherus BioSciences (NASDAQ:CHRS) Receives “Buy” Rating from HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the biotechnology company’s stock.

Separately, Robert W. Baird raised their target price on Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $5.38.

Coherus BioSciences Stock Performance

CHRS opened at $1.04 on Tuesday. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $2.64. The firm has a market cap of $120.53 million, a price-to-earnings ratio of -13.00 and a beta of 0.92. The company has a fifty day simple moving average of $1.25 and a 200 day simple moving average of $1.19.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CHRS. Bank of Montreal Can bought a new position in Coherus BioSciences during the fourth quarter worth $34,000. Steph & Co. acquired a new stake in shares of Coherus BioSciences during the fourth quarter worth $34,000. Systematic Financial Management LP bought a new position in shares of Coherus BioSciences in the 3rd quarter worth about $28,000. Intech Investment Management LLC acquired a new position in shares of Coherus BioSciences in the 4th quarter valued at about $38,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Coherus BioSciences during the 4th quarter valued at about $52,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.